Patent 10221207 was granted and assigned to SomaLogic, Inc. on March, 2019 by the United States Patent and Trademark Office.
The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same.